Pharma & Healthcare
Global Vigabatrin Market Research Report 2025
- Jul 28, 25
- ID: 409154
- Pages: 91
- Figures: 88
- Views: 6
The global market for Vigabatrin was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Vigabatrin is a medication used to treat epilepsy. It became available as a generic medication in 2019. It works by inhibiting the breakdown of γ-aminobutyric acid (GABA). It is also known as γ-vinyl-GABA, and is a structural analogue of GABA, but does not bind to GABA receptors.
North American market for Vigabatrin is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Vigabatrin is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Vigabatrin include Sanofi, Benta Pharma Industries, Dr. Fisher Farma, Lundbeck, Novartis, Perrigo, Grindeks, Endo International, Amneal Pharma, Cipla, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Vigabatrin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vigabatrin.
The Vigabatrin market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Vigabatrin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Vigabatrin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Sanofi
Benta Pharma Industries
Dr. Fisher Farma
Lundbeck
Novartis
Perrigo
Grindeks
Endo International
Amneal Pharma
Cipla
Upsher-Smith
Segment by Type
Tablet
Powder
Segment by Application
Infantile Spasms (IS)
Partial-Onset Seizures
Refractory Complex Partial Seizures
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Vigabatrin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Vigabatrin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Vigabatrin is a medication used to treat epilepsy. It became available as a generic medication in 2019. It works by inhibiting the breakdown of γ-aminobutyric acid (GABA). It is also known as γ-vinyl-GABA, and is a structural analogue of GABA, but does not bind to GABA receptors.
North American market for Vigabatrin is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Vigabatrin is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Vigabatrin include Sanofi, Benta Pharma Industries, Dr. Fisher Farma, Lundbeck, Novartis, Perrigo, Grindeks, Endo International, Amneal Pharma, Cipla, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Vigabatrin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vigabatrin.
The Vigabatrin market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Vigabatrin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Vigabatrin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Sanofi
Benta Pharma Industries
Dr. Fisher Farma
Lundbeck
Novartis
Perrigo
Grindeks
Endo International
Amneal Pharma
Cipla
Upsher-Smith
Segment by Type
Tablet
Powder
Segment by Application
Infantile Spasms (IS)
Partial-Onset Seizures
Refractory Complex Partial Seizures
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Vigabatrin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Vigabatrin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Vigabatrin Market Overview
1.1 Product Definition
1.2 Vigabatrin by Type
1.2.1 Global Vigabatrin Market Value Comparison by Type (2024 VS 2031)
1.2.2 Tablet
1.2.3 Powder
1.3 Vigabatrin by Application
1.3.1 Global Vigabatrin Market Value by Application (2024 VS 2031)
1.3.2 Infantile Spasms (IS)
1.3.3 Partial-Onset Seizures
1.3.4 Refractory Complex Partial Seizures
1.4 Global Vigabatrin Market Size Estimates and Forecasts
1.4.1 Global Vigabatrin Revenue 2020-2031
1.4.2 Global Vigabatrin Sales 2020-2031
1.4.3 Global Vigabatrin Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Vigabatrin Market Competition by Manufacturers
2.1 Global Vigabatrin Sales Market Share by Manufacturers (2020-2025)
2.2 Global Vigabatrin Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Vigabatrin Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Vigabatrin, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Vigabatrin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Vigabatrin, Product Type & Application
2.7 Global Key Manufacturers of Vigabatrin, Date of Enter into This Industry
2.8 Global Vigabatrin Market Competitive Situation and Trends
2.8.1 Global Vigabatrin Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Vigabatrin Players Market Share by Revenue
2.8.3 Global Vigabatrin Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Vigabatrin Market Scenario by Region
3.1 Global Vigabatrin Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Vigabatrin Sales by Region: 2020-2031
3.2.1 Global Vigabatrin Sales by Region: 2020-2025
3.2.2 Global Vigabatrin Sales by Region: 2026-2031
3.3 Global Vigabatrin Revenue by Region: 2020-2031
3.3.1 Global Vigabatrin Revenue by Region: 2020-2025
3.3.2 Global Vigabatrin Revenue by Region: 2026-2031
3.4 North America Vigabatrin Market Facts & Figures by Country
3.4.1 North America Vigabatrin Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Vigabatrin Sales by Country (2020-2031)
3.4.3 North America Vigabatrin Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Vigabatrin Market Facts & Figures by Country
3.5.1 Europe Vigabatrin Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Vigabatrin Sales by Country (2020-2031)
3.5.3 Europe Vigabatrin Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Vigabatrin Market Facts & Figures by Region
3.6.1 Asia Pacific Vigabatrin Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Vigabatrin Sales by Region (2020-2031)
3.6.3 Asia Pacific Vigabatrin Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Vigabatrin Market Facts & Figures by Country
3.7.1 Latin America Vigabatrin Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Vigabatrin Sales by Country (2020-2031)
3.7.3 Latin America Vigabatrin Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Vigabatrin Market Facts & Figures by Country
3.8.1 Middle East and Africa Vigabatrin Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Vigabatrin Sales by Country (2020-2031)
3.8.3 Middle East and Africa Vigabatrin Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Vigabatrin Sales by Type (2020-2031)
4.1.1 Global Vigabatrin Sales by Type (2020-2025)
4.1.2 Global Vigabatrin Sales by Type (2026-2031)
4.1.3 Global Vigabatrin Sales Market Share by Type (2020-2031)
4.2 Global Vigabatrin Revenue by Type (2020-2031)
4.2.1 Global Vigabatrin Revenue by Type (2020-2025)
4.2.2 Global Vigabatrin Revenue by Type (2026-2031)
4.2.3 Global Vigabatrin Revenue Market Share by Type (2020-2031)
4.3 Global Vigabatrin Price by Type (2020-2031)
5 Segment by Application
5.1 Global Vigabatrin Sales by Application (2020-2031)
5.1.1 Global Vigabatrin Sales by Application (2020-2025)
5.1.2 Global Vigabatrin Sales by Application (2026-2031)
5.1.3 Global Vigabatrin Sales Market Share by Application (2020-2031)
5.2 Global Vigabatrin Revenue by Application (2020-2031)
5.2.1 Global Vigabatrin Revenue by Application (2020-2025)
5.2.2 Global Vigabatrin Revenue by Application (2026-2031)
5.2.3 Global Vigabatrin Revenue Market Share by Application (2020-2031)
5.3 Global Vigabatrin Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Sanofi
6.1.1 Sanofi Company Information
6.1.2 Sanofi Description and Business Overview
6.1.3 Sanofi Vigabatrin Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Sanofi Vigabatrin Product Portfolio
6.1.5 Sanofi Recent Developments/Updates
6.2 Benta Pharma Industries
6.2.1 Benta Pharma Industries Company Information
6.2.2 Benta Pharma Industries Description and Business Overview
6.2.3 Benta Pharma Industries Vigabatrin Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Benta Pharma Industries Vigabatrin Product Portfolio
6.2.5 Benta Pharma Industries Recent Developments/Updates
6.3 Dr. Fisher Farma
6.3.1 Dr. Fisher Farma Company Information
6.3.2 Dr. Fisher Farma Description and Business Overview
6.3.3 Dr. Fisher Farma Vigabatrin Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Dr. Fisher Farma Vigabatrin Product Portfolio
6.3.5 Dr. Fisher Farma Recent Developments/Updates
6.4 Lundbeck
6.4.1 Lundbeck Company Information
6.4.2 Lundbeck Description and Business Overview
6.4.3 Lundbeck Vigabatrin Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Lundbeck Vigabatrin Product Portfolio
6.4.5 Lundbeck Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Company Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis Vigabatrin Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Novartis Vigabatrin Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Perrigo
6.6.1 Perrigo Company Information
6.6.2 Perrigo Description and Business Overview
6.6.3 Perrigo Vigabatrin Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Perrigo Vigabatrin Product Portfolio
6.6.5 Perrigo Recent Developments/Updates
6.7 Grindeks
6.7.1 Grindeks Company Information
6.7.2 Grindeks Description and Business Overview
6.7.3 Grindeks Vigabatrin Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Grindeks Vigabatrin Product Portfolio
6.7.5 Grindeks Recent Developments/Updates
6.8 Endo International
6.8.1 Endo International Company Information
6.8.2 Endo International Description and Business Overview
6.8.3 Endo International Vigabatrin Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Endo International Vigabatrin Product Portfolio
6.8.5 Endo International Recent Developments/Updates
6.9 Amneal Pharma
6.9.1 Amneal Pharma Company Information
6.9.2 Amneal Pharma Description and Business Overview
6.9.3 Amneal Pharma Vigabatrin Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Amneal Pharma Vigabatrin Product Portfolio
6.9.5 Amneal Pharma Recent Developments/Updates
6.10 Cipla
6.10.1 Cipla Company Information
6.10.2 Cipla Description and Business Overview
6.10.3 Cipla Vigabatrin Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Cipla Vigabatrin Product Portfolio
6.10.5 Cipla Recent Developments/Updates
6.11 Upsher-Smith
6.11.1 Upsher-Smith Company Information
6.11.2 Upsher-Smith Description and Business Overview
6.11.3 Upsher-Smith Vigabatrin Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Upsher-Smith Vigabatrin Product Portfolio
6.11.5 Upsher-Smith Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Vigabatrin Industry Chain Analysis
7.2 Vigabatrin Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Vigabatrin Production Mode & Process Analysis
7.4 Vigabatrin Sales and Marketing
7.4.1 Vigabatrin Sales Channels
7.4.2 Vigabatrin Distributors
7.5 Vigabatrin Customer Analysis
8 Vigabatrin Market Dynamics
8.1 Vigabatrin Industry Trends
8.2 Vigabatrin Market Drivers
8.3 Vigabatrin Market Challenges
8.4 Vigabatrin Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Vigabatrin by Type
1.2.1 Global Vigabatrin Market Value Comparison by Type (2024 VS 2031)
1.2.2 Tablet
1.2.3 Powder
1.3 Vigabatrin by Application
1.3.1 Global Vigabatrin Market Value by Application (2024 VS 2031)
1.3.2 Infantile Spasms (IS)
1.3.3 Partial-Onset Seizures
1.3.4 Refractory Complex Partial Seizures
1.4 Global Vigabatrin Market Size Estimates and Forecasts
1.4.1 Global Vigabatrin Revenue 2020-2031
1.4.2 Global Vigabatrin Sales 2020-2031
1.4.3 Global Vigabatrin Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Vigabatrin Market Competition by Manufacturers
2.1 Global Vigabatrin Sales Market Share by Manufacturers (2020-2025)
2.2 Global Vigabatrin Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Vigabatrin Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Vigabatrin, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Vigabatrin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Vigabatrin, Product Type & Application
2.7 Global Key Manufacturers of Vigabatrin, Date of Enter into This Industry
2.8 Global Vigabatrin Market Competitive Situation and Trends
2.8.1 Global Vigabatrin Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Vigabatrin Players Market Share by Revenue
2.8.3 Global Vigabatrin Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Vigabatrin Market Scenario by Region
3.1 Global Vigabatrin Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Vigabatrin Sales by Region: 2020-2031
3.2.1 Global Vigabatrin Sales by Region: 2020-2025
3.2.2 Global Vigabatrin Sales by Region: 2026-2031
3.3 Global Vigabatrin Revenue by Region: 2020-2031
3.3.1 Global Vigabatrin Revenue by Region: 2020-2025
3.3.2 Global Vigabatrin Revenue by Region: 2026-2031
3.4 North America Vigabatrin Market Facts & Figures by Country
3.4.1 North America Vigabatrin Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Vigabatrin Sales by Country (2020-2031)
3.4.3 North America Vigabatrin Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Vigabatrin Market Facts & Figures by Country
3.5.1 Europe Vigabatrin Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Vigabatrin Sales by Country (2020-2031)
3.5.3 Europe Vigabatrin Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Vigabatrin Market Facts & Figures by Region
3.6.1 Asia Pacific Vigabatrin Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Vigabatrin Sales by Region (2020-2031)
3.6.3 Asia Pacific Vigabatrin Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Vigabatrin Market Facts & Figures by Country
3.7.1 Latin America Vigabatrin Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Vigabatrin Sales by Country (2020-2031)
3.7.3 Latin America Vigabatrin Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Vigabatrin Market Facts & Figures by Country
3.8.1 Middle East and Africa Vigabatrin Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Vigabatrin Sales by Country (2020-2031)
3.8.3 Middle East and Africa Vigabatrin Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Vigabatrin Sales by Type (2020-2031)
4.1.1 Global Vigabatrin Sales by Type (2020-2025)
4.1.2 Global Vigabatrin Sales by Type (2026-2031)
4.1.3 Global Vigabatrin Sales Market Share by Type (2020-2031)
4.2 Global Vigabatrin Revenue by Type (2020-2031)
4.2.1 Global Vigabatrin Revenue by Type (2020-2025)
4.2.2 Global Vigabatrin Revenue by Type (2026-2031)
4.2.3 Global Vigabatrin Revenue Market Share by Type (2020-2031)
4.3 Global Vigabatrin Price by Type (2020-2031)
5 Segment by Application
5.1 Global Vigabatrin Sales by Application (2020-2031)
5.1.1 Global Vigabatrin Sales by Application (2020-2025)
5.1.2 Global Vigabatrin Sales by Application (2026-2031)
5.1.3 Global Vigabatrin Sales Market Share by Application (2020-2031)
5.2 Global Vigabatrin Revenue by Application (2020-2031)
5.2.1 Global Vigabatrin Revenue by Application (2020-2025)
5.2.2 Global Vigabatrin Revenue by Application (2026-2031)
5.2.3 Global Vigabatrin Revenue Market Share by Application (2020-2031)
5.3 Global Vigabatrin Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Sanofi
6.1.1 Sanofi Company Information
6.1.2 Sanofi Description and Business Overview
6.1.3 Sanofi Vigabatrin Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Sanofi Vigabatrin Product Portfolio
6.1.5 Sanofi Recent Developments/Updates
6.2 Benta Pharma Industries
6.2.1 Benta Pharma Industries Company Information
6.2.2 Benta Pharma Industries Description and Business Overview
6.2.3 Benta Pharma Industries Vigabatrin Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Benta Pharma Industries Vigabatrin Product Portfolio
6.2.5 Benta Pharma Industries Recent Developments/Updates
6.3 Dr. Fisher Farma
6.3.1 Dr. Fisher Farma Company Information
6.3.2 Dr. Fisher Farma Description and Business Overview
6.3.3 Dr. Fisher Farma Vigabatrin Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Dr. Fisher Farma Vigabatrin Product Portfolio
6.3.5 Dr. Fisher Farma Recent Developments/Updates
6.4 Lundbeck
6.4.1 Lundbeck Company Information
6.4.2 Lundbeck Description and Business Overview
6.4.3 Lundbeck Vigabatrin Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Lundbeck Vigabatrin Product Portfolio
6.4.5 Lundbeck Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Company Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis Vigabatrin Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Novartis Vigabatrin Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Perrigo
6.6.1 Perrigo Company Information
6.6.2 Perrigo Description and Business Overview
6.6.3 Perrigo Vigabatrin Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Perrigo Vigabatrin Product Portfolio
6.6.5 Perrigo Recent Developments/Updates
6.7 Grindeks
6.7.1 Grindeks Company Information
6.7.2 Grindeks Description and Business Overview
6.7.3 Grindeks Vigabatrin Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Grindeks Vigabatrin Product Portfolio
6.7.5 Grindeks Recent Developments/Updates
6.8 Endo International
6.8.1 Endo International Company Information
6.8.2 Endo International Description and Business Overview
6.8.3 Endo International Vigabatrin Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Endo International Vigabatrin Product Portfolio
6.8.5 Endo International Recent Developments/Updates
6.9 Amneal Pharma
6.9.1 Amneal Pharma Company Information
6.9.2 Amneal Pharma Description and Business Overview
6.9.3 Amneal Pharma Vigabatrin Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Amneal Pharma Vigabatrin Product Portfolio
6.9.5 Amneal Pharma Recent Developments/Updates
6.10 Cipla
6.10.1 Cipla Company Information
6.10.2 Cipla Description and Business Overview
6.10.3 Cipla Vigabatrin Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Cipla Vigabatrin Product Portfolio
6.10.5 Cipla Recent Developments/Updates
6.11 Upsher-Smith
6.11.1 Upsher-Smith Company Information
6.11.2 Upsher-Smith Description and Business Overview
6.11.3 Upsher-Smith Vigabatrin Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Upsher-Smith Vigabatrin Product Portfolio
6.11.5 Upsher-Smith Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Vigabatrin Industry Chain Analysis
7.2 Vigabatrin Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Vigabatrin Production Mode & Process Analysis
7.4 Vigabatrin Sales and Marketing
7.4.1 Vigabatrin Sales Channels
7.4.2 Vigabatrin Distributors
7.5 Vigabatrin Customer Analysis
8 Vigabatrin Market Dynamics
8.1 Vigabatrin Industry Trends
8.2 Vigabatrin Market Drivers
8.3 Vigabatrin Market Challenges
8.4 Vigabatrin Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Vigabatrin Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Vigabatrin Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Vigabatrin Market Competitive Situation by Manufacturers in 2024
Table 4. Global Vigabatrin Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Vigabatrin Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Vigabatrin Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Vigabatrin Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Vigabatrin Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Vigabatrin, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Vigabatrin, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Vigabatrin, Product Type & Application
Table 12. Global Key Manufacturers of Vigabatrin, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Vigabatrin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vigabatrin as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Vigabatrin Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Vigabatrin Sales by Region (2020-2025) & (K Units)
Table 18. Global Vigabatrin Sales Market Share by Region (2020-2025)
Table 19. Global Vigabatrin Sales by Region (2026-2031) & (K Units)
Table 20. Global Vigabatrin Sales Market Share by Region (2026-2031)
Table 21. Global Vigabatrin Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Vigabatrin Revenue Market Share by Region (2020-2025)
Table 23. Global Vigabatrin Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Vigabatrin Revenue Market Share by Region (2026-2031)
Table 25. North America Vigabatrin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Vigabatrin Sales by Country (2020-2025) & (K Units)
Table 27. North America Vigabatrin Sales by Country (2026-2031) & (K Units)
Table 28. North America Vigabatrin Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Vigabatrin Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Vigabatrin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Vigabatrin Sales by Country (2020-2025) & (K Units)
Table 32. Europe Vigabatrin Sales by Country (2026-2031) & (K Units)
Table 33. Europe Vigabatrin Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Vigabatrin Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Vigabatrin Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Vigabatrin Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Vigabatrin Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Vigabatrin Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Vigabatrin Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Vigabatrin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Vigabatrin Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Vigabatrin Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Vigabatrin Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Vigabatrin Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Vigabatrin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Vigabatrin Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Vigabatrin Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Vigabatrin Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Vigabatrin Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Vigabatrin Sales (K Units) by Type (2020-2025)
Table 51. Global Vigabatrin Sales (K Units) by Type (2026-2031)
Table 52. Global Vigabatrin Sales Market Share by Type (2020-2025)
Table 53. Global Vigabatrin Sales Market Share by Type (2026-2031)
Table 54. Global Vigabatrin Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Vigabatrin Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Vigabatrin Revenue Market Share by Type (2020-2025)
Table 57. Global Vigabatrin Revenue Market Share by Type (2026-2031)
Table 58. Global Vigabatrin Price (US$/Unit) by Type (2020-2025)
Table 59. Global Vigabatrin Price (US$/Unit) by Type (2026-2031)
Table 60. Global Vigabatrin Sales (K Units) by Application (2020-2025)
Table 61. Global Vigabatrin Sales (K Units) by Application (2026-2031)
Table 62. Global Vigabatrin Sales Market Share by Application (2020-2025)
Table 63. Global Vigabatrin Sales Market Share by Application (2026-2031)
Table 64. Global Vigabatrin Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Vigabatrin Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Vigabatrin Revenue Market Share by Application (2020-2025)
Table 67. Global Vigabatrin Revenue Market Share by Application (2026-2031)
Table 68. Global Vigabatrin Price (US$/Unit) by Application (2020-2025)
Table 69. Global Vigabatrin Price (US$/Unit) by Application (2026-2031)
Table 70. Sanofi Company Information
Table 71. Sanofi Description and Business Overview
Table 72. Sanofi Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Sanofi Vigabatrin Product
Table 74. Sanofi Recent Developments/Updates
Table 75. Benta Pharma Industries Company Information
Table 76. Benta Pharma Industries Description and Business Overview
Table 77. Benta Pharma Industries Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Benta Pharma Industries Vigabatrin Product
Table 79. Benta Pharma Industries Recent Developments/Updates
Table 80. Dr. Fisher Farma Company Information
Table 81. Dr. Fisher Farma Description and Business Overview
Table 82. Dr. Fisher Farma Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Dr. Fisher Farma Vigabatrin Product
Table 84. Dr. Fisher Farma Recent Developments/Updates
Table 85. Lundbeck Company Information
Table 86. Lundbeck Description and Business Overview
Table 87. Lundbeck Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Lundbeck Vigabatrin Product
Table 89. Lundbeck Recent Developments/Updates
Table 90. Novartis Company Information
Table 91. Novartis Description and Business Overview
Table 92. Novartis Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Novartis Vigabatrin Product
Table 94. Novartis Recent Developments/Updates
Table 95. Perrigo Company Information
Table 96. Perrigo Description and Business Overview
Table 97. Perrigo Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Perrigo Vigabatrin Product
Table 99. Perrigo Recent Developments/Updates
Table 100. Grindeks Company Information
Table 101. Grindeks Description and Business Overview
Table 102. Grindeks Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Grindeks Vigabatrin Product
Table 104. Grindeks Recent Developments/Updates
Table 105. Endo International Company Information
Table 106. Endo International Description and Business Overview
Table 107. Endo International Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Endo International Vigabatrin Product
Table 109. Endo International Recent Developments/Updates
Table 110. Amneal Pharma Company Information
Table 111. Amneal Pharma Description and Business Overview
Table 112. Amneal Pharma Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Amneal Pharma Vigabatrin Product
Table 114. Amneal Pharma Recent Developments/Updates
Table 115. Cipla Company Information
Table 116. Cipla Description and Business Overview
Table 117. Cipla Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Cipla Vigabatrin Product
Table 119. Cipla Recent Developments/Updates
Table 120. Upsher-Smith Company Information
Table 121. Upsher-Smith Description and Business Overview
Table 122. Upsher-Smith Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Upsher-Smith Vigabatrin Product
Table 124. Upsher-Smith Recent Developments/Updates
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. Vigabatrin Distributors List
Table 128. Vigabatrin Customers List
Table 129. Vigabatrin Market Trends
Table 130. Vigabatrin Market Drivers
Table 131. Vigabatrin Market Challenges
Table 132. Vigabatrin Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
Table 136. Authors List of This Report
List of Figures
Figure 1. Product Picture of Vigabatrin
Figure 2. Global Vigabatrin Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Vigabatrin Market Share by Type: 2024 & 2031
Figure 4. Tablet Product Picture
Figure 5. Powder Product Picture
Figure 6. Global Vigabatrin Market Value by Application (2020-2031) & (US$ Million)
Figure 7. Global Vigabatrin Market Share by Application: 2024 & 2031
Figure 8. Infantile Spasms (IS)
Figure 9. Partial-Onset Seizures
Figure 10. Refractory Complex Partial Seizures
Figure 11. Global Vigabatrin Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Vigabatrin Market Size (2020-2031) & (US$ Million)
Figure 13. Global Vigabatrin Sales (2020-2031) & (K Units)
Figure 14. Global Vigabatrin Average Price (US$/Unit) & (2020-2031)
Figure 15. Vigabatrin Report Years Considered
Figure 16. Vigabatrin Sales Share by Manufacturers in 2024
Figure 17. Global Vigabatrin Revenue Share by Manufacturers in 2024
Figure 18. Global 5 and 10 Largest Vigabatrin Players: Market Share by Revenue in Vigabatrin in 2024
Figure 19. Vigabatrin Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 20. Global Vigabatrin Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 21. North America Vigabatrin Sales Market Share by Country (2020-2031)
Figure 22. North America Vigabatrin Revenue Market Share by Country (2020-2031)
Figure 23. United States Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 24. Canada Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Europe Vigabatrin Sales Market Share by Country (2020-2031)
Figure 26. Europe Vigabatrin Revenue Market Share by Country (2020-2031)
Figure 27. Germany Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. France Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. U.K. Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. Italy Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Russia Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Asia Pacific Vigabatrin Sales Market Share by Region (2020-2031)
Figure 33. Asia Pacific Vigabatrin Revenue Market Share by Region (2020-2031)
Figure 34. China Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Japan Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. South Korea Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. India Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Australia Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. China Taiwan Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Indonesia Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Thailand Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Malaysia Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Latin America Vigabatrin Sales Market Share by Country (2020-2031)
Figure 44. Latin America Vigabatrin Revenue Market Share by Country (2020-2031)
Figure 45. Mexico Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Brazil Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Argentina Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Middle East and Africa Vigabatrin Sales Market Share by Country (2020-2031)
Figure 49. Middle East and Africa Vigabatrin Revenue Market Share by Country (2020-2031)
Figure 50. Turkey Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Saudi Arabia Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. UAE Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Global Sales Market Share of Vigabatrin by Type (2020-2031)
Figure 54. Global Revenue Market Share of Vigabatrin by Type (2020-2031)
Figure 55. Global Vigabatrin Price (US$/Unit) by Type (2020-2031)
Figure 56. Global Sales Market Share of Vigabatrin by Application (2020-2031)
Figure 57. Global Revenue Market Share of Vigabatrin by Application (2020-2031)
Figure 58. Global Vigabatrin Price (US$/Unit) by Application (2020-2031)
Figure 59. Vigabatrin Value Chain
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Table 1. Global Vigabatrin Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Vigabatrin Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Vigabatrin Market Competitive Situation by Manufacturers in 2024
Table 4. Global Vigabatrin Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Vigabatrin Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Vigabatrin Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Vigabatrin Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Vigabatrin Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Vigabatrin, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Vigabatrin, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Vigabatrin, Product Type & Application
Table 12. Global Key Manufacturers of Vigabatrin, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Vigabatrin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vigabatrin as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Vigabatrin Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Vigabatrin Sales by Region (2020-2025) & (K Units)
Table 18. Global Vigabatrin Sales Market Share by Region (2020-2025)
Table 19. Global Vigabatrin Sales by Region (2026-2031) & (K Units)
Table 20. Global Vigabatrin Sales Market Share by Region (2026-2031)
Table 21. Global Vigabatrin Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Vigabatrin Revenue Market Share by Region (2020-2025)
Table 23. Global Vigabatrin Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Vigabatrin Revenue Market Share by Region (2026-2031)
Table 25. North America Vigabatrin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Vigabatrin Sales by Country (2020-2025) & (K Units)
Table 27. North America Vigabatrin Sales by Country (2026-2031) & (K Units)
Table 28. North America Vigabatrin Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Vigabatrin Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Vigabatrin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Vigabatrin Sales by Country (2020-2025) & (K Units)
Table 32. Europe Vigabatrin Sales by Country (2026-2031) & (K Units)
Table 33. Europe Vigabatrin Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Vigabatrin Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Vigabatrin Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Vigabatrin Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Vigabatrin Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Vigabatrin Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Vigabatrin Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Vigabatrin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Vigabatrin Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Vigabatrin Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Vigabatrin Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Vigabatrin Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Vigabatrin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Vigabatrin Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Vigabatrin Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Vigabatrin Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Vigabatrin Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Vigabatrin Sales (K Units) by Type (2020-2025)
Table 51. Global Vigabatrin Sales (K Units) by Type (2026-2031)
Table 52. Global Vigabatrin Sales Market Share by Type (2020-2025)
Table 53. Global Vigabatrin Sales Market Share by Type (2026-2031)
Table 54. Global Vigabatrin Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Vigabatrin Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Vigabatrin Revenue Market Share by Type (2020-2025)
Table 57. Global Vigabatrin Revenue Market Share by Type (2026-2031)
Table 58. Global Vigabatrin Price (US$/Unit) by Type (2020-2025)
Table 59. Global Vigabatrin Price (US$/Unit) by Type (2026-2031)
Table 60. Global Vigabatrin Sales (K Units) by Application (2020-2025)
Table 61. Global Vigabatrin Sales (K Units) by Application (2026-2031)
Table 62. Global Vigabatrin Sales Market Share by Application (2020-2025)
Table 63. Global Vigabatrin Sales Market Share by Application (2026-2031)
Table 64. Global Vigabatrin Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Vigabatrin Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Vigabatrin Revenue Market Share by Application (2020-2025)
Table 67. Global Vigabatrin Revenue Market Share by Application (2026-2031)
Table 68. Global Vigabatrin Price (US$/Unit) by Application (2020-2025)
Table 69. Global Vigabatrin Price (US$/Unit) by Application (2026-2031)
Table 70. Sanofi Company Information
Table 71. Sanofi Description and Business Overview
Table 72. Sanofi Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Sanofi Vigabatrin Product
Table 74. Sanofi Recent Developments/Updates
Table 75. Benta Pharma Industries Company Information
Table 76. Benta Pharma Industries Description and Business Overview
Table 77. Benta Pharma Industries Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Benta Pharma Industries Vigabatrin Product
Table 79. Benta Pharma Industries Recent Developments/Updates
Table 80. Dr. Fisher Farma Company Information
Table 81. Dr. Fisher Farma Description and Business Overview
Table 82. Dr. Fisher Farma Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Dr. Fisher Farma Vigabatrin Product
Table 84. Dr. Fisher Farma Recent Developments/Updates
Table 85. Lundbeck Company Information
Table 86. Lundbeck Description and Business Overview
Table 87. Lundbeck Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Lundbeck Vigabatrin Product
Table 89. Lundbeck Recent Developments/Updates
Table 90. Novartis Company Information
Table 91. Novartis Description and Business Overview
Table 92. Novartis Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Novartis Vigabatrin Product
Table 94. Novartis Recent Developments/Updates
Table 95. Perrigo Company Information
Table 96. Perrigo Description and Business Overview
Table 97. Perrigo Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Perrigo Vigabatrin Product
Table 99. Perrigo Recent Developments/Updates
Table 100. Grindeks Company Information
Table 101. Grindeks Description and Business Overview
Table 102. Grindeks Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Grindeks Vigabatrin Product
Table 104. Grindeks Recent Developments/Updates
Table 105. Endo International Company Information
Table 106. Endo International Description and Business Overview
Table 107. Endo International Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Endo International Vigabatrin Product
Table 109. Endo International Recent Developments/Updates
Table 110. Amneal Pharma Company Information
Table 111. Amneal Pharma Description and Business Overview
Table 112. Amneal Pharma Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Amneal Pharma Vigabatrin Product
Table 114. Amneal Pharma Recent Developments/Updates
Table 115. Cipla Company Information
Table 116. Cipla Description and Business Overview
Table 117. Cipla Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Cipla Vigabatrin Product
Table 119. Cipla Recent Developments/Updates
Table 120. Upsher-Smith Company Information
Table 121. Upsher-Smith Description and Business Overview
Table 122. Upsher-Smith Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Upsher-Smith Vigabatrin Product
Table 124. Upsher-Smith Recent Developments/Updates
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. Vigabatrin Distributors List
Table 128. Vigabatrin Customers List
Table 129. Vigabatrin Market Trends
Table 130. Vigabatrin Market Drivers
Table 131. Vigabatrin Market Challenges
Table 132. Vigabatrin Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
Table 136. Authors List of This Report
List of Figures
Figure 1. Product Picture of Vigabatrin
Figure 2. Global Vigabatrin Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Vigabatrin Market Share by Type: 2024 & 2031
Figure 4. Tablet Product Picture
Figure 5. Powder Product Picture
Figure 6. Global Vigabatrin Market Value by Application (2020-2031) & (US$ Million)
Figure 7. Global Vigabatrin Market Share by Application: 2024 & 2031
Figure 8. Infantile Spasms (IS)
Figure 9. Partial-Onset Seizures
Figure 10. Refractory Complex Partial Seizures
Figure 11. Global Vigabatrin Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Vigabatrin Market Size (2020-2031) & (US$ Million)
Figure 13. Global Vigabatrin Sales (2020-2031) & (K Units)
Figure 14. Global Vigabatrin Average Price (US$/Unit) & (2020-2031)
Figure 15. Vigabatrin Report Years Considered
Figure 16. Vigabatrin Sales Share by Manufacturers in 2024
Figure 17. Global Vigabatrin Revenue Share by Manufacturers in 2024
Figure 18. Global 5 and 10 Largest Vigabatrin Players: Market Share by Revenue in Vigabatrin in 2024
Figure 19. Vigabatrin Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 20. Global Vigabatrin Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 21. North America Vigabatrin Sales Market Share by Country (2020-2031)
Figure 22. North America Vigabatrin Revenue Market Share by Country (2020-2031)
Figure 23. United States Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 24. Canada Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Europe Vigabatrin Sales Market Share by Country (2020-2031)
Figure 26. Europe Vigabatrin Revenue Market Share by Country (2020-2031)
Figure 27. Germany Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. France Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. U.K. Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. Italy Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Russia Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Asia Pacific Vigabatrin Sales Market Share by Region (2020-2031)
Figure 33. Asia Pacific Vigabatrin Revenue Market Share by Region (2020-2031)
Figure 34. China Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Japan Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. South Korea Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. India Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Australia Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. China Taiwan Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Indonesia Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Thailand Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Malaysia Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Latin America Vigabatrin Sales Market Share by Country (2020-2031)
Figure 44. Latin America Vigabatrin Revenue Market Share by Country (2020-2031)
Figure 45. Mexico Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Brazil Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Argentina Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Middle East and Africa Vigabatrin Sales Market Share by Country (2020-2031)
Figure 49. Middle East and Africa Vigabatrin Revenue Market Share by Country (2020-2031)
Figure 50. Turkey Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Saudi Arabia Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. UAE Vigabatrin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Global Sales Market Share of Vigabatrin by Type (2020-2031)
Figure 54. Global Revenue Market Share of Vigabatrin by Type (2020-2031)
Figure 55. Global Vigabatrin Price (US$/Unit) by Type (2020-2031)
Figure 56. Global Sales Market Share of Vigabatrin by Application (2020-2031)
Figure 57. Global Revenue Market Share of Vigabatrin by Application (2020-2031)
Figure 58. Global Vigabatrin Price (US$/Unit) by Application (2020-2031)
Figure 59. Vigabatrin Value Chain
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Fatigue Analysis Engineering Services Market Research Report 2025
Jul 29, 25
Global Blast Impact Analysis Engineering Services Market Research Report 2025
Jul 29, 25
Global On-Line Analytical Processing (OLAP) Business Intelligence Consulting Services Market Research Report 2025
Jul 29, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232